Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes After Cardiac Surgery: A Pilot Study
- PMID: 40779436
- PMCID: PMC12753113
- DOI: 10.1213/ANE.0000000000007705
Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes After Cardiac Surgery: A Pilot Study
Conflict of interest statement
Conflicts of Interest, Funding: Please see DISCLOSURES at the end of this article.
References
-
- McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;44:3627–3639. - PubMed
-
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–3726. - PubMed
-
- Oosterom-Eijmael MJP, Hermanides J, van Raalte DH, Hulst AH. Risk of perioperative discontinuation of SGLT2 inhibitors. Br J Anaesth. 2024;133:239–240. - PubMed
-
- Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). Eur Heart J. 2022;43:3826–3924.
-
- Pölzl L, Engler C, Sterzinger P, et al. Association of high-sensitivity cardiac troponin T with 30-day and 5-year mortality after cardiac surgery. J Am Coll Cardiol. 2023;82:1301–1312. - PubMed
LinkOut - more resources
Full Text Sources
